RxDoctor Payments Data

Nida Khan, MD

Ophthalmology · Allentown, PANPI 1255745667

Payments from drug & device makers

$1,691in general payments, 2019–2025

Across 45 payments — averaging $37.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$405
  • AbbVie$341
  • Alcon$227
  • Sight Sciences, Inc.$168
  • Bausch & Lomb Americas Inc.$99
  • Medtronic$97
  • plus $355 from 12 others

What the payments were for

  • Food & beverage$1,691100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,691 in reported general payments places this provider in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$167,975
Medicare patients
502
Services billed
1,294

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine231$255,599
XiidraLifitegrast76$92,724
Cyclosporine72$38,440
LumiganBimatoprost60$38,031
Prednisolone Acetate282$11,933
Restasis MultidoseCyclosporine11$9,669
Latanoprost412$5,952
Ketorolac Tromethamine190$4,207
Brimonidine Tartrate118$3,900
TobradexTobramycin/Dexamethasone13$3,432
Ofloxacin194$3,262
Timolol Maleate71$1,415
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat50$1,175
ErythromycinErythromycin Base34$351
ValacyclovirValacyclovir Hcl11$311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose$341$303,298302 claims
Bausch & Lomb Americas Inc.Xiidra$99$92,72476 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →